<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="86633">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01977352</url>
  </required_header>
  <id_info>
    <org_study_id>13-0064</org_study_id>
    <nct_id>NCT01977352</nct_id>
  </id_info>
  <brief_title>Efficacy of Interscalene Brachial Plexus Block With Liposomal Bupivacaine for Arthroscopic Shoulder Surgery</brief_title>
  <official_title>Comparison of Cumulative Opioid Consumption After Interscalene Brachial Plexus Block With Liposomal Bupivacaine (Exparel; 88 mg in 20 cc) Versus Bupivacaine 0.25% for Arthroscopic Shoulder Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's-Roosevelt Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Luke's-Roosevelt Hospital Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the quality and duration of pain relief after
      shoulder surgery provided by a single injection of liposomal bupivacaine versus standard
      bupivacaine when administered as an interscalene brachial plexus block. It is hypothesized
      that the liposomal bupivacaine formulation will provide more effective pain relief than
      standard bupivacaine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total opioid consumption</measure>
    <time_frame>72 hours</time_frame>
    <description>Compare total opioid consumption up to 72 hours post operatively between patients receiving bupivacaine 0.25% (20 cc) and liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc) for interscalene brachial plexus block.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of analgesia</measure>
    <time_frame>1 week</time_frame>
    <description>Quality of analgesia as measured by numerical rating scores (NRS-11) at 24, 48, 72 hours and 1 week postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset and duration of sensory block</measure>
    <time_frame>72 hours</time_frame>
    <description>Measurement of brachial plexus blockade will be carried out every 5 min up to 30 minutes upon completion of the peripheral nerve block and prior to surgery. Sensory block will be assessed by pinprick with a paper clip using a 0-2 scale: 0, no block (complete sensation); 1, parasthesia (light touch); 2, anesthesia (no sensation). Evaluation of sensory block will also be undertaken at one and two hours after arrival to the Post Anesthesia Care Unit (PACU). The first occurrence of pain perceived by the patient will be used as a surrogate for return of the sensory function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first pain medicine</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge home</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of postoperative nausea and vomiting</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Shoulder Pain</condition>
  <condition>Rotator Cuff Tear</condition>
  <arm_group>
    <arm_group_label>Bupivacaine 0.25%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 cc of bupivacaine 0.25%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)</description>
    <arm_group_label>Bupivacaine 0.25%</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine 0.25%</intervention_name>
    <description>20 cc of bupivacaine 0.25%</description>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
    <other_name>Bupivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  English speaking adults (age &gt;17 years) of American Society of Anesthesiologists
             (ASA) I-III physical class scheduled for elective arthroscopic shoulder surgery will
             be eligible to participate regardless of race/ethnicity.

        Exclusion Criteria:

          -  Subjects will not be eligible for this trial if they report a history of an allergy
             to a local anesthetic, baseline neurological deficit, a medical condition that would
             make it difficult to assess sensory distribution or communicate with the staff, a
             recent history (&lt; 3 months) of drug or alcohol abuse, concomitant opioid therapy, or
             a preexisting coagulation disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Shariat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's-Roosevelt Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Luke's Roosevelt Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>June 2, 2015</lastchanged_date>
  <firstreceived_date>October 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exparel</keyword>
  <keyword>Liposomal Bupivacaine</keyword>
  <keyword>Arthroscopic Shoulder Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Shoulder Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
